Outcomes and diffusion of doxorubicin-based chemotherapy among elderly patients with aggressive non-Hodgkin lymphoma.

@article{Grann2006OutcomesAD,
  title={Outcomes and diffusion of doxorubicin-based chemotherapy among elderly patients with aggressive non-Hodgkin lymphoma.},
  author={Victor R. Grann and Dawn L. Hershman and Judith S. Jacobson and W Y Tsai and Jian Wang and Russell B McBride and Nandita Mitra and Michael L. Grossbard and Alfred I. Neugut},
  journal={Cancer},
  year={2006},
  volume={107 7},
  pages={1530-41}
}
BACKGROUND In the past 25 years, clinical trials have demonstrated the benefits of chemotherapy for patients with aggressive non-Hodgkin lymphoma. The authors analyzed the predictors and outcomes of chemotherapy among elderly patients with lymphoma. METHODS Patients age >/=65 years who were diagnosed with Stage III and IV diffuse large B-cell lymphoma [according to the SEER Summary Staging Manual, 2000] between 1991 and 1999 in the Surveillance, Epidemiology, and End Results-Medicare data… CONTINUE READING